Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial

…, WF Chase, RK Dore, CW Wiesenhutter… - Archives of internal …, 2002 - jamanetwork.com
Background Cevimeline hydrochloride is a cholinergic agent with muscarinic agonist activity
prominently affecting the M1 and M3 receptors prevalent in exocrine glands. We evaluated …

Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene …

…, GE Graham, CW Wiesenhutter… - The Journal of …, 2010 - jrheum.org
Objective. To assess safety and clinical outcomes in patients with inflammatory arthritis after
intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector …

Is sarcoidosis an autoimmune disease?: Report of four cases and review of the literature

CW Wiesenhutter, OP Sharma - Seminars in arthritis and rheumatism, 1979 - Elsevier
Four cases of sarcoidosis coexisting with connective tissue diseases are described: three
cases of sarcoidosis coexisting with PSS, and one case of sarcoidosis coexisting with SLE. …

Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial

CW Wiesenhutter, JA Boice, A Ko, EA Sheldon… - Mayo Clinic …, 2005 - Elsevier
OBJECTIVE To directly compare the efficacy and safety of etoricoxib, 30 mg once daily,
ibuprofen, 800 mg 3 times daily, and placebo for treatment of osteoarthritis (OA) of the hip and …

Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: A pilot trial.

CW Wiesenhutter, BL Irish… - The Journal of …, 1994 - europepmc.org
Objective To evaluate the safety and effectiveness of extracorporeal immunoadsorption with
protein A (PROSORBA) columns in the treatment of refractory rheumatoid arthritis (RA). …

The low-throughput protein A adsorber: an immune modulatory device. Hypothesis for the mechanism of action in the treatment of rheumatoid arthritis

…, RE Voll, JR Kalden, CW Wiesenhutter… - Modern …, 2005 - Taylor & Francis
To achieve specific removal of pathogenic antibodies (Ab) or immune complexes (IC),
several adsorbers have been developed. We discuss the mode of action of low-throughput …

In vitro t lymphocyte proliferative response to yersinia enterocolitica in reiter's syndrome

…, S Kobayashi, CW Wiesenhutter… - … : Official Journal of …, 1984 - Wiley Online Library
We assessed the in vitro T lymphocyte tritiated thymidine ( 3 HTdr) incorporation response
of Reiter's patients in the United States to a serotype 3 strain of Yersinia enterocolitica. The …

Adverse Effects of Etoricoxib: Other Considerations: In Response

JA Boice, CW Wiesenhutter - Mayo Clinic Proceedings, 2005 - mayoclinicproceedings.org
1. Wiesenhutter CW, Boice JA, Ko A, et al, Protocol 071 Study Group. Evaluation of the
comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a …

AB0343 Treatment of Rheumatoid Arthritis Patients with Parenteral Staphylococcal Protein A (PRTX-100): An Open-Label Single-Site Extension Trial

C Wiesenhutter - 2016 - ard.bmj.com
Background Staphylococcal protein A (SpA) is a bacterial B-cell superantigen that binds with
high affinity to the Fc region of most immunoglobulins (Igs) and to the Fab framework region …

THU0086 The use of a blinded truncated ultrasound power doppler joint count validates efficacy data from an early phase open label drug study treating rheumatoid …

C Wiesenhutter - 2017 - ard.bmj.com
… These UPDs were stored digitally and subsequently read in duplicate in a blinded fashion
after completion of the study by the investigator (CW). Each joint site was subjectively scored …